Background Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with
psoriasis have been reported. Objectives To assess the prevalence and incidence of PsA in …

Patients with psoriasis are at an increased risk of metabolic syndrome (MetS); however, a
systematic analysis of its global prevalence has not been performed to date. Here, we …

Background Psoriasis is a very prevalent systemic chronic inflammatory disease. Major
cardiovascular events are the main cause of mortality in these patients which suggests an …

Objectives To examine the incidence and temporal trends of psoriatic arthritis (PsA) in the
general population in Denmark. Methods Using nationwide registry data, we estimated the …

Background: Coexistence of obesity, hypertension, insulin resistance and dyslipidemia is
defined as metabolic syndrome (MBS), which is among the important risk indicators for …

Objectives Increased cardiovascular risk in rheumatoid arthritis (RA) is well established.
Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in …

Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease that affects
peripheral joints, entheses and axial sites in addition to both skin and nails. There is …

Psoriasis is a systemic inflammatory disorder that can target adipose tissue; the resulting
adipocyte dysfunction is manifest clinically as the metabolic syndrome, which is present in≈ …

Introduction Certolizumab pegol (CZP), the Fc-free, PEGylated anti-tumor necrosis factor, is
approved for the treatment of moderate to severe plaque psoriasis (PSO) in Western …

Introduction A strong link has been established between psoriasis and lipid disturbances;
however, no study has systematically examined their global epidemiology. Methods We …